1-8 of 8
Cristina Quarta
Close
Sort by
Journal Articles

Safety and Tolerability of Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24-Month Results of a Phase 2 Study

Jason Valent, Michaela Liedtke, Jeffrey A. Zonder, Richa Manwani, Chandrasekhar Udata, Juliana Ianus, John Tripptree, Julia Catini, Candida Cristina Quarta
Journal: Blood
Blood (2023) 142 (Supplement 1): 540.
https://doi.org/10.1182/blood-2023-186515
Published: 2023
Journal Articles

1-Year Results from a Phase 2 Study to Determine Safety and Tolerability of Treating Patients with Light-Chain (AL) Amyloidosis with Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia

Jason Valent, Michaela Liedtke, Jeffrey A. Zonder, Mark Tulchinskiy, Chandrasekhar Udata, Girly Ramirez, Kate Szymaniak, Julia Catini, Candida Cristina Quarta
Journal: Blood
Blood (2022) 140 (Supplement 1): 10127–10128.
https://doi.org/10.1182/blood-2022-162597
Published: 2022
Journal Articles

C11-1F4 Binds and Promotes Clearance of Light Chain Fibrils By Phagocytosis

Sahar Esteghamat, Dhirender Ahlawat, Steve Raiker, Melissa Batonick, Candida Cristina Quarta, Sahar Usmani-Brown
Journal: Blood
Blood (2022) 140 (Supplement 1): 12442–12443.
https://doi.org/10.1182/blood-2022-159766
Published: 2022
Journal Articles

Evaluation of the Path to Diagnosis and Time to Treatment in Patients with Light-Chain Amyloidosis Using the Komodo Claims Database

Julia Catini, Quan Doan, Jennifer Evans, Andrew Rava, Thomas Defay, Guillermo Del Angel, Megan Teynor, Candida Cristina Quarta, Mathew S. Maurer, Isabelle Lousada
Journal: Blood
Blood (2022) 140 (Supplement 1): 4330–4331.
https://doi.org/10.1182/blood-2022-162694
Published: 2022
Journal Articles

Cardiac Amyloid Reaching for Extended Survival (CARES): Study Design of Two Placebo-Controlled, Double-Blind, Randomized, International Phase 3 Trials Assessing Cael-101 in Patients with Mayo Stage Iiia or Stage IIIb AL Amyloidosis

Ashutosh D. Wechalekar, John Silowsky, Eileen Daniel, Mark Harnett, Michael Spector, Susan B. Sobolov, Candida Cristina Quarta, Michael R. Kurman, Mark Tulchinskiy, Amit Bhattacharyya, Michaela Liedtke
Journal: Blood
Blood (2021) 138 (Supplement 1): 1673.
https://doi.org/10.1182/blood-2021-152488
Published: 2021
Journal Articles

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Clinical Trials & Observations
Richa Manwani, Oliver Cohen, Faye Sharpley, Shameem Mahmood, Sajitha Sachchithanantham, Darren Foard, Helen J. Lachmann, Cristina Quarta, Marianna Fontana, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar
Journal: Blood
Blood (2019) 134 (25): 2271–2280.
https://doi.org/10.1182/blood.2019000834
Published: 2019
Journal Articles

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine

Clinical Trials & Observations
Richa Manwani, Sajitha Sachchithanantham, Shameem Mahmood, Darren Foard, Faye Sharpley, Tamer Rezk, Thirusha Lane, Cristina Quarta, Marianna Fontana, Helen J. Lachmann, Julian D. Gillmore, Carol Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar
Journal: Blood
Blood (2018) 132 (7): 761–764.
https://doi.org/10.1182/blood-2018-04-846493
Published: 2018
Journal Articles

A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis

Belen Sevillano, Haematology Specialist, Ashutosh Wechalekar, MDFRCPath FRCP, Darren Foard, Specialist Nurse, Carol Whelan, MDFRCP, Marianna Fontana, MD, Cristina Quarta, Shameem Mahmood, FRCPath, Helen Lachmann, MDFRCP, Julian D Gillmore, MDPhDFRCP, Philip N Hawkins, MDPhDFMedSci
Journal: Blood
Blood (2015) 126 (23): 5357.
https://doi.org/10.1182/blood.V126.23.5357.5357
Published: 2015